Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -101.16% is 34% below its 5-year average of -75.58%, around the middle of its 5-year range (-184.95%–-19.28%).
12.62% below its 12-month average of -89.82%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -112.95%.
EBITDA MARGIN
-101.16%
EBITDA MARGIN AVG TTM
-89.82%
EBITDA MARGIN AVG 3Y
-83.83%
EBITDA MARGIN AVG 5Y
-75.58%
EBITDA MARGIN AVG 10Y
-52.38%
EBITDA MARGIN AVG 15Y
-43.63%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-12.62%
CURRENT VS 3Y AVG
-20.67%
CURRENT VS 5Y AVG
-33.85%
CURRENT VS 10Y AVG
-93.12%
CURRENT VS 15Y AVG
-131.88%
CURRENT VS 20Y AVG
N/A
Standard BioTools Inc.
Market Cap
$292.07M
EBITDA Margin
-101.16%
TTM Avg
-89.82%
3Y Avg
-83.83%
5Y Avg
-75.58%
Market Cap
$286.94M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$281.16M
EBITDA Margin
-25.38%
TTM Avg
-1946.60%
3Y Avg
-1509.96%
5Y Avg
-1364.90%
Market Cap
$279.56M
EBITDA Margin
-1475.69%
TTM Avg
-1475.69%
3Y Avg
-2002.71%
5Y Avg
-1922.41%
Market Cap
$306.01M
EBITDA Margin
-24933.33%
TTM Avg
-24426.94%
3Y Avg
-19832.71%
5Y Avg
-13250.84%
Market Cap
$306.66M
EBITDA Margin
-144.24%
TTM Avg
-144.24%
3Y Avg
-144.24%
5Y Avg
-144.24%
Market Cap
$275.95M
EBITDA Margin
-13.37%
TTM Avg
-2.68%
3Y Avg
-19.85%
5Y Avg
-36.16%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Standard BioTools Inc. (LAB) | $292.07M | -101.16% | -89.82% | -83.83% | -75.58% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $286.94M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $285.16M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.16M | -25.38% | -1946.60% | -1509.96% | -1364.90% |
| Abeona Therapeutics Inc. (ABEO)vs › | $279.56M | -1475.69% | -1475.69% | -2002.71% | -1922.41% |
| Benitec Biopharma Inc. (BNTC)vs › | $306.01M | -24933.33% | -24426.94% | -19832.71% | -13250.84% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $306.66M | -144.24% | -144.24% | -144.24% | -144.24% |
| Aurora Cannabis Inc. (ACB)vs › | $275.95M | -13.37% | -2.68% | -19.85% | -36.16% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $272.91M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $272.17M | -2082.59% | -1743.06% | -1015.79% | -806.48% |
Gross Margin
49.1%
EBITDA Margin
-101.2%
Operating Margin
-109.3%
Net Margin
-103.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -112.95% |
| 2026-03-31 | -37.87% |
| 2025-12-31 | -86.73% |
| 2025-09-30 | -111.86% |
| 2025-06-30 | -99.71% |
| 2025-03-31 | -99.12% |
| 2024-12-31 | -61.78% |
| 2024-09-30 | -61.95% |
| 2024-06-30 | -117.40% |
| 2024-03-31 | -120.75% |
| 2023-12-31 | -62.01% |
| 2023-09-30 | -67.75% |
| 2023-06-30 | -49.96% |
| 2023-03-31 | -51.48% |
| 2022-12-31 | -64.74% |
| 2022-09-30 | -99.14% |
| 2022-06-30 | -184.95% |
| 2022-03-31 | -88.79% |
| 2021-12-31 | -19.28% |
| 2021-09-30 | -55.22% |
| 2021-06-30 | -43.10% |
| 2021-03-31 | -46.97% |
| 2020-12-31 | -28.91% |
| 2020-09-30 | -3.76% |
| 2020-06-30 | -37.74% |
| 2020-03-31 | -39.40% |
| 2019-12-31 | -16.21% |
| 2019-09-30 | -37.30% |
| 2019-06-30 | -37.86% |
| 2019-03-31 | -33.92% |
| 2018-12-31 | -21.87% |
| 2018-09-30 | -37.01% |
| 2018-06-30 | -22.53% |
| 2018-03-31 | -31.09% |
| 2017-12-31 | -15.66% |
| 2017-09-30 | -44.73% |
| 2017-06-30 | -48.30% |
| 2017-03-31 | -50.07% |
| 2016-12-31 | -52.35% |
| 2016-09-30 | -62.89% |
| 2016-06-30 | -48.50% |
| 2016-03-31 | -50.01% |
| 2015-12-31 | -32.57% |
| 2015-09-30 | -13.10% |
| 2015-06-30 | -36.40% |
| 2015-03-31 | -36.90% |
| 2014-12-31 | -25.96% |
| 2014-09-30 | -40.38% |
| 2014-06-30 | -41.36% |
| 2014-03-31 | -61.02% |
| 2013-12-31 | -15.52% |
| 2013-09-30 | -23.49% |
| 2013-06-30 | -19.34% |
| 2013-03-31 | -30.84% |
| 2012-12-31 | -19.54% |
| 2012-09-30 | -27.77% |
| 2012-06-30 | -31.12% |
| 2012-03-31 | -54.38% |
| 2011-12-31 | -21.75% |
| 2011-09-30 | -34.43% |
| 2011-06-30 | -61.45% |
| 2011-03-31 | -52.09% |
| 2010-12-31 | -16.13% |
| 2010-09-30 | -30.32% |
| 2010-06-30 | -49.84% |
| 2010-03-31 | -71.96% |
| 2009-12-31 | -44.02% |
